Trenton, February 25, 2026 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), released the following statement concerning the “Most Favored Nation” drug pricing proposal referenced in last night’s State of the Union address:
“New Jersey and America lead the world in drug discovery and curing diseases, and lowering health care costs is a bipartisan goal. We’ve partnered with lawmakers on both sides of the aisle and with this and previous Administrations on policies that do so without harming patients or threatening future treatments and cures.”
Buteas continued, “There are right ways and wrong ways to lower the cost of healthcare. Codification of a mandatory, one-size-fits-all approach of importing socialized medicine price controls will jeopardize New Jersey’s and America’s historic position as the global leader in innovation at the exact moment China is working desperately to overtake our leadership. That is a threat to patients and our national security.”
Buteas concluded, “Lowering costs for patients is among the highest of priorities, one that must be coupled with the continued discovery of new, revolutionary ways to save patients’ lives from cancers and other dreaded diseases. We will continue working with our executive and legislative leaders in Trenton and Washington on policies that make sense for patients and America’s global leadership.”